NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has reported progress in its Phase IIA clinical trial evaluating NV-387 Oral Gummies for the treatment of Ebola Bundibugyo virus infection in the Democratic Republic of Congo. The exploratory trial is designed to enroll up to 20 patients with varying disease severity and is assessing the safety and tolerability of treatment regimens ranging from six to 12 days. Although the study is not designed to establish statistically significant efficacy, the company said it may identify preliminary signs of antiviral activity.
Following completion of the trial and evaluation of the results, NanoViricides plans to advance an appropriate dosing regimen into an expanded, randomized, controlled Phase IIB study, provided the findings support further development. NV-387 is a broad-spectrum antiviral candidate designed to reduce viral load by targeting host-cell features used by viruses during infection. The company’s pipeline includes NV-387 for respiratory viral infections such as RSV, COVID, and influenza, as well as MPOX/Smallpox and measles, and NV-HHV-1 for shingles.
The trial’s progress is significant as Ebola remains a deadly viral disease with limited treatment options, particularly in outbreak-prone regions like the Democratic Republic of Congo. If NV-387 demonstrates safety and preliminary antiviral activity, it could represent a new oral treatment approach that is easier to administer in resource-limited settings. The company’s broad-spectrum platform, based on TheraCour Pharma’s nanomedicine technology, aims to create special purpose nanomaterials for antiviral therapy. NanoViricides holds exclusive licenses for several viral diseases, including Ebola/Marburg viruses.
For investors, the update signals advancement in a high-risk, high-reward area of drug development. The company’s lead drug candidate, NV-387, is also being developed for other indications, and successful results could lead to broader applications. However, as with any drug development, there can be no assurance that the candidates will show sufficient effectiveness and safety for human clinical development. The path to typical drug development is lengthy and requires substantial capital.
The latest news and updates relating to NNVC are available in the company’s newsroom at https://nnw.fm/NNVC. NetworkNewsWire, a specialized communications platform, is covering this development as part of its financial news and content distribution services. NetworkNewsWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which offers access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions.
For more information about NanoViricides, visit www.nanoviricides.com. To view the full press release, visit https://nnw.fm/9fDB5. Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer.
